Mission
Our goal of this Co-Clinical Imaging Research Program (CIRP) (Project Number: 1U24CA253377) is to overcome the translational barrier, to develop co-clinical imaging research resources that will encourage a consensus on how quantitative imaging methods are optimized to improve the quality of imaging results for co-clinical trials. This will be accomplished by using novel quantitative metabolic preclinical hyperpolarized (HP) 13C magnetic resonance imaging (MRI) to assess therapeutic response of small cell neuroendocrine (SCNC) prostate cancer (PCa). Although this proposal will focus on current standard of care treatment, the new quantitative HP 13C metabolic MRI approaches developed in this proposal will have general applicability for a variety of new targeted therapeutic approaches being developed for SCNC as well as for the study of other diseases.
Website Resources
This Co-Clinical Imaging Research Program website is a portal for quantitative HP 13C MRI protocols, data analyses tools, and correlative biology data which will provide a better understanding on how quantitative HP 13C MRI can be used in co-clinical imaging trials to improve the assessment of therapeutic response and resistance. While this project focuses on advanced prostate cancer, these new quantitative metabolic imaging techniques could ultimately benefit the clinical management of other cancers and diseases.
Events
HMTRC 2025 Workshop
The April 2025 Hyperpolarized Carbon-13 MRI Technology Development Workshop was held on April 3rd-4th 2025. The workshop included lectures, hands-on training and discussions on dissolution DNP methodology, polarizer instrumentation, MR Sequence and Acquisitions, Pre-clinical HP Chemistry Preps, Human HP Investigational Dose Formulation & Production, Clinical Translation Methods, Clinical Trial Research, and Analysis & Display Software.
Please click here to view the 2025 HMTRC Workshop Recordings